Cellectis (CLLS) Says FDA Grants IND Approval to Proceed with Clinical Development of UCART123 – StreetInsider.com
Cellectis (CLLS) Says FDA Grants IND Approval to Proceed with Clinical Development of UCART123
StreetInsider.com Cellectis (NASDAQ: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to … Cellectis gets green light to start clinical trials in US with UCART123; shares ahead 9% after hours Cellectis gets US go-ahead to test ‘off-the-shelf’ cell therapy |
View original article
Author:
Powered by WPeMatico